Proteins



Product Data Sheet

AlbA-DCA

Cat. No.: HY-130117 CAS No.: 2413716-79-5 Molecular Formula: $C_{43}H_{67}Cl_2NO_{12}$

Molecular Weight: 860.9

Target: Reactive Oxygen Species; Apoptosis

Pathway: Immunology/Inflammation; Metabolic Enzyme/Protease; NF-кВ; Apoptosis

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

BIOLOGICAL ACTIVITY

Description AlbA-DCA is a conjugate formed by the attachment of Albiziabioside A (AlbA) to a dichloroacetate acid (DCA) subunit. AlbA-DCA can induce a marked increase in intracellular ROS and alleviate the accumulation of lactic acid in tumor

microenvironment (TME), and also selectively kills cancer cells and induce apoptosis^[1].

ROS^[1]IC₅₀ & Target

In Vitro AlbA-DCA exhibits the cytotoxicity against the MCF-7 cells, HCT116 cells, A375 cells, 4T1 cells, HBMEC cells and LO2 cells with IC_{50} values of 0.43 μ M, 3.87 μ M, 3.78 μ M, 1.31 μ M, 38.20 μ M and 53.14 μ M, respectively^[1].

AlbA-DCA (2 μM; 24 hours; MCF-7 cells) treatment induces apoptotic cell death in MCF-7 cells^[1].

caspase-9.

AlbA-DCA (2 μM; MCF-7 cells) treatment could significantly up-regulate the expression of cytochrome c and down-regulate the expression of antiapoptotic protein Bcl-2. AlbA-DCA significantly enhances the expression of caspase-9^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Apoptosis Ariatysis	
Cell Line:	MCF-7 cells
Concentration:	2 μΜ
Incubation Time:	24 hours
Result:	Induced apoptosis of MCF-7 cells.
Western Blot Analysis ^[1]	
Cell Line:	MCF-7 cells
Concentration:	2 μΜ
Incubation Time:	
Result:	Could significantly up-regulate the expression of cytochrome c and down-regulate the

In Vivo

AlbA-DCA (2 mg/kg; subcutaneous injection; every 2 days; for 2 weeks; nude mice) treatment displays antitumor efficacy and

expression of antiapoptotic protein Bcl-2. Significantly enhanced the expression of

almost completely suppresses tumor progression, and no mouse deaths and no significant changes in body weight are observed. AlbA-DCA has no obvious toxicity of liver and kidney and no major abnormality is observed in heart, liver, spleen, lung, and kidney^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing MCF-7 $tumors^{[1]}$
Dosage:	2 mg/kg
Administration:	Subcutaneous injection; every 2 days; for 2 weeks
Result:	Displayed the best antitumor efficacy and almost completely suppressed tumor progression.

REFERENCES

[1]. Wei G, et al. Natural Product Albiziabioside A Conjugated with Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate To Induce Apoptosis-Ferroptosis-M2-TAMs Polarization for Combined Cancer Therapy. J Med Chem. 2019 Oct 10;62(19):8760-8772.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA